M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.9 EUR 0.25%
Market Cap: 109.8m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maat Pharma SA
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Research & Development
-€20.9m
CAGR 3-Years
-51%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Research & Development
-€95.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Research & Development
-€47.1m
CAGR 3-Years
-12%
CAGR 5-Years
4%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Research & Development
-€29.7m
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Research & Development
-€99.8m
CAGR 3-Years
-50%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Research & Development
-€5.7m
CAGR 3-Years
-32%
CAGR 5-Years
-29%
CAGR 10-Years
1%
No Stocks Found

Maat Pharma SA
Glance View

Market Cap
110m EUR
Industry
Biotechnology

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

MAAT Intrinsic Value
7.21 EUR
Overvaluation 9%
Intrinsic Value
Price
M

See Also

What is Maat Pharma SA's Research & Development?
Research & Development
-20.9m EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Research & Development amounts to -20.9m EUR.

What is Maat Pharma SA's Research & Development growth rate?
Research & Development CAGR 5Y
-36%

Over the last year, the Research & Development growth was -46%. The average annual Research & Development growth rates for Maat Pharma SA have been -51% over the past three years , -36% over the past five years .

Back to Top